康弘药业
(002773)
| 流通市值：197.49亿 | | | 总市值：264.92亿 |
| 流通股本：6.87亿 | | | 总股本：9.21亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 3,436,381,809.82 | 5,689,515,722.69 | 3,325,058,811.52 | 2,999,322,489.68 |
| 应收票据及应收账款 | 198,059,160.95 | 177,851,805.2 | 174,620,154.83 | 217,366,726.06 |
| 其中：应收票据 | 600,000 | 371,112 | 532,080.6 | - |
| 应收账款 | 197,459,160.95 | 177,480,693.2 | 174,088,074.23 | 217,366,726.06 |
| 预付款项 | 31,492,509.6 | 11,456,537.64 | 41,589,916.99 | 25,533,757.43 |
| 其他应收款合计 | 11,751,625.86 | 3,780,682.1 | 16,530,155.99 | 12,184,809.85 |
| 存货 | 364,324,959.17 | 386,855,892.63 | 404,423,005.53 | 417,320,387.48 |
| 其他流动资产 | 16,061,120.13 | 19,358,763.92 | 21,047,676.39 | 22,750,607.3 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 6,698,071,185.53 | 6,288,819,404.18 | 6,203,269,721.25 | 5,814,478,777.8 |
| 非流动资产: | | | | |
| 长期股权投资 | 16,306,817.06 | 16,441,178.64 | 16,576,602.6 | 16,670,226.02 |
| 固定资产 | 2,188,293,315.9 | 2,230,431,309.9 | 2,222,635,614.51 | 2,266,615,715.27 |
| 在建工程 | 122,576,261.7 | 112,350,071.44 | 89,551,708.5 | 75,981,770.72 |
| 生产性生物资产 | 4,358,789.34 | 4,651,636.86 | 5,433,810.85 | 5,889,576.68 |
| 使用权资产 | 4,850,150.38 | 5,289,470.94 | 5,939,456.96 | 5,566,625.58 |
| 无形资产 | 279,267,686.89 | 286,886,964.18 | 293,598,905.32 | 301,322,918.29 |
| 开发支出 | 122,222,787.52 | 116,808,232.03 | 106,209,937.04 | 94,477,752.56 |
| 长期待摊费用 | 5,553,913.43 | 6,431,061.17 | 4,811,592.45 | 5,865,751.92 |
| 递延所得税资产 | 215,834,843.56 | 259,458,576.66 | 242,661,487.49 | 271,938,140.79 |
| 其他非流动资产 | 15,402,153.4 | 14,368,433.67 | 22,140,256.47 | 16,765,557.25 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,974,666,719.18 | 3,053,116,935.49 | 3,009,559,372.19 | 3,061,094,035.08 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 9,672,737,904.71 | 9,341,936,339.67 | 9,212,829,093.44 | 8,875,572,812.88 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 243,922,288.01 | 297,163,828.81 | 243,735,576.47 | 266,523,629.79 |
| 应付账款 | 243,922,288.01 | 297,163,828.81 | 243,735,576.47 | 266,523,629.79 |
| 预收款项 | 7,979,671.02 | 4,572,971.54 | 4,853,502.52 | 4,350,841.11 |
| 合同负债 | 9,764,827.25 | 8,923,034.45 | 3,815,902.29 | 6,526,433.85 |
| 应付职工薪酬 | 43,052,292.22 | 147,281,964.61 | 24,452,329.41 | 41,797,318.03 |
| 应交税费 | 60,376,870.7 | 51,485,912.97 | 51,195,410.18 | 50,060,584.88 |
| 其他应付款合计 | 197,879,788.43 | 62,844,654 | 336,635,176.41 | 240,745,117.04 |
| 一年内到期的非流动负债 | 1,426,435.91 | 1,733,930.1 | 2,406,915.38 | 2,379,090.59 |
| 其他流动负债 | 21,485,008.38 | 80,985,720.2 | 68,397,330.91 | 57,761,841.03 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 585,887,181.92 | 654,992,016.68 | 735,492,143.57 | 670,144,856.32 |
| 非流动负债: | | | | |
| 租赁负债 | 2,312,115.97 | 3,467,492.1 | 3,875,876.37 | 3,235,485.25 |
| 长期应付款 | 6,748,666.19 | 7,088,541.51 | 10,122,093.41 | 17,664,219.71 |
| 递延收益 | 19,003,424.52 | 16,487,733.41 | 17,704,042.3 | 18,120,351.19 |
| 递延所得税负债 | 13,332,369.74 | 13,033,476.07 | 11,054,552.41 | 10,444,869.77 |
| 其他非流动负债 | 240,506.61 | - | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 41,637,083.03 | 40,077,243.09 | 42,756,564.49 | 49,464,925.92 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 627,524,264.95 | 695,069,259.77 | 778,248,708.06 | 719,609,782.24 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 919,869,004 | 919,778,254 | 919,778,254 | 919,756,504 |
| 资本公积 | 1,998,487,172.29 | 1,996,607,436.63 | 1,996,600,785.93 | 1,996,681,168.14 |
| 其他综合收益 | -1,846,417.48 | -1,327,725.21 | -1,489,530.04 | -1,811,781.2 |
| 盈余公积 | 515,315,206.97 | 515,315,206.97 | 515,315,206.97 | 515,315,206.97 |
| 未分配利润 | 5,622,846,636.45 | 5,222,828,957.76 | 5,005,309,774.87 | 4,723,818,236.77 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 9,054,671,602.23 | 8,653,202,130.15 | 8,435,514,491.73 | 8,153,759,334.68 |
| 少数股东权益 | -9,457,962.47 | -6,335,050.25 | -934,106.35 | 2,203,695.96 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 9,045,213,639.76 | 8,646,867,079.9 | 8,434,580,385.38 | 8,155,963,030.64 |
| 负债和股东权益合计 | 9,672,737,904.71 | 9,341,936,339.67 | 9,212,829,093.44 | 8,875,572,812.88 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-25 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |